Vimarsana
Biggest News Aggregation in the World

Roberto Bellini News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roberto Bellini. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roberto Bellini Today - Breaking & Trending Today

GALLERY: Hundreds celebrate at Nescol graduations - Vimarsana News

GALLERY: Hundreds celebrate at Nescol graduations

North East Scotland College (Nescol) students from both the Aberdeen City Campus and Altens Campus celebrated their graduations today.

Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month - Vimarsana News

Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month

The US$14.75-a-share deal, which goes to the Quebec Superior Court next week for approval, is the latest in a series of US$1-billion-plus takeovers of Canadian life sciences companies

BELLUS Health : AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 - Form 6-K - Vimarsana News

BELLUS Health : AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 - Form 6-K

AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 May 31,... | June 10, 2023

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Vimarsana News

BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights

- Announced agreement to be acquired by GSK for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion and a premium of approximately 103%;... | May 12, 2023

GSK to spend £1.6 billion on Canadian maker of blockbuster cough drug Camlipixant - Vimarsana News

GSK to spend £1.6 billion on Canadian maker of blockbuster cough drug Camlipixant

The deal is the biggest since the old GlaxoSmithKline split in two by separating its consumer products arm